Back to today’s briefing

Story perspectives

Alzheimer’s Trials Under Fire for Genetic Transparency Breach

1/22/2025

47 8

Summary

Story summary

Eisai and Eli Lilly faced backlash for conducting Alzheimer’s drug trials without informing participants of their ApoE4 genetic status, a factor that heightens the risk of brain bleeds. Critics label this a serious breach of informed consent, while others contend the connection was not well understood then. Today, transparency about genetic risks is mandatory.

1 of 1

Story summary

Eisai and Eli Lilly faced backlash for conducting Alzheimer’s drug trials without informing participants of their ApoE4 genetic status, a factor that heightens the risk of brain bleeds. Critics label this a serious breach of informed consent, while others contend the connection was not well understood then. Today, transparency about genetic risks is mandatory.